ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer

Abdul Fattah Salah Fararjeh, Yen Nien Liu

Research output: Contribution to journalReview article

Abstract

Prostate cancer (PCa) is the second most common killer among men in Western countries. Targeting androgen receptor (AR) signaling by androgen deprivation therapy (ADT) is the current therapeutic regime for patients newly diagnosed with metastatic PCa. However, most patients relapse and become resistant to ADT, leading to metastatic castration-resistant PCa (CRPC) and eventually death. Several proposed mechanisms have been proposed for CRPC; however, the exact mechanism through which CRPC develops is still unclear. One possible pathway is that the AR remains active in CRPC cases. Therefore, understanding AR signaling networks as primary PCa changes into metastatic CRPC is key to developing future biomarkers and therapeutic strategies for PCa and CRPC. In the current review, we focused on three novel biomarkers (ZBTB46, SPDEF, and ETV6) that were demonstrated to play critical roles in CRPC progression, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug resistance, and the epithelial-to-mesenchymal transition (EMT) for patients treated with ADT or AR inhibition. In addition, we summarize how these potential biomarkers can be used in the clinic for diagnosis and as therapeutic targets of PCa.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume20
Issue number11
DOIs
Publication statusPublished - Jun 8 2019

Fingerprint

biomarkers
Castration
Androgen Receptors
Biomarkers
Prostatic Neoplasms
cancer
deprivation
Androgens
therapy
Therapeutics
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
tyrosine
Epithelial-Mesenchymal Transition
death
progressions
inhibitors
Drug Resistance
drugs
Pharmaceutical Preparations

Keywords

  • androgen receptor (AR)
  • castration-resistant prostate cancer (CRPC)
  • ETS variant gene 6 (ETV6)
  • SAM pointed domain containing ETS transcriptional factor (SPDEF)
  • zinc finger and BTB domain-containing protein 46 (ZBTB46)

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

ZBTB46, SPDEF, and ETV6 : Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer. / Fararjeh, Abdul Fattah Salah; Liu, Yen Nien.

In: International Journal of Molecular Sciences, Vol. 20, No. 11, 08.06.2019.

Research output: Contribution to journalReview article

@article{6ca20c49fcae45fd8a5c47b028ea21be,
title = "ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer",
abstract = "Prostate cancer (PCa) is the second most common killer among men in Western countries. Targeting androgen receptor (AR) signaling by androgen deprivation therapy (ADT) is the current therapeutic regime for patients newly diagnosed with metastatic PCa. However, most patients relapse and become resistant to ADT, leading to metastatic castration-resistant PCa (CRPC) and eventually death. Several proposed mechanisms have been proposed for CRPC; however, the exact mechanism through which CRPC develops is still unclear. One possible pathway is that the AR remains active in CRPC cases. Therefore, understanding AR signaling networks as primary PCa changes into metastatic CRPC is key to developing future biomarkers and therapeutic strategies for PCa and CRPC. In the current review, we focused on three novel biomarkers (ZBTB46, SPDEF, and ETV6) that were demonstrated to play critical roles in CRPC progression, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug resistance, and the epithelial-to-mesenchymal transition (EMT) for patients treated with ADT or AR inhibition. In addition, we summarize how these potential biomarkers can be used in the clinic for diagnosis and as therapeutic targets of PCa.",
keywords = "androgen receptor (AR), castration-resistant prostate cancer (CRPC), ETS variant gene 6 (ETV6), SAM pointed domain containing ETS transcriptional factor (SPDEF), zinc finger and BTB domain-containing protein 46 (ZBTB46)",
author = "Fararjeh, {Abdul Fattah Salah} and Liu, {Yen Nien}",
year = "2019",
month = "6",
day = "8",
doi = "10.3390/ijms20112802",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "11",

}

TY - JOUR

T1 - ZBTB46, SPDEF, and ETV6

T2 - Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer

AU - Fararjeh, Abdul Fattah Salah

AU - Liu, Yen Nien

PY - 2019/6/8

Y1 - 2019/6/8

N2 - Prostate cancer (PCa) is the second most common killer among men in Western countries. Targeting androgen receptor (AR) signaling by androgen deprivation therapy (ADT) is the current therapeutic regime for patients newly diagnosed with metastatic PCa. However, most patients relapse and become resistant to ADT, leading to metastatic castration-resistant PCa (CRPC) and eventually death. Several proposed mechanisms have been proposed for CRPC; however, the exact mechanism through which CRPC develops is still unclear. One possible pathway is that the AR remains active in CRPC cases. Therefore, understanding AR signaling networks as primary PCa changes into metastatic CRPC is key to developing future biomarkers and therapeutic strategies for PCa and CRPC. In the current review, we focused on three novel biomarkers (ZBTB46, SPDEF, and ETV6) that were demonstrated to play critical roles in CRPC progression, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug resistance, and the epithelial-to-mesenchymal transition (EMT) for patients treated with ADT or AR inhibition. In addition, we summarize how these potential biomarkers can be used in the clinic for diagnosis and as therapeutic targets of PCa.

AB - Prostate cancer (PCa) is the second most common killer among men in Western countries. Targeting androgen receptor (AR) signaling by androgen deprivation therapy (ADT) is the current therapeutic regime for patients newly diagnosed with metastatic PCa. However, most patients relapse and become resistant to ADT, leading to metastatic castration-resistant PCa (CRPC) and eventually death. Several proposed mechanisms have been proposed for CRPC; however, the exact mechanism through which CRPC develops is still unclear. One possible pathway is that the AR remains active in CRPC cases. Therefore, understanding AR signaling networks as primary PCa changes into metastatic CRPC is key to developing future biomarkers and therapeutic strategies for PCa and CRPC. In the current review, we focused on three novel biomarkers (ZBTB46, SPDEF, and ETV6) that were demonstrated to play critical roles in CRPC progression, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug resistance, and the epithelial-to-mesenchymal transition (EMT) for patients treated with ADT or AR inhibition. In addition, we summarize how these potential biomarkers can be used in the clinic for diagnosis and as therapeutic targets of PCa.

KW - androgen receptor (AR)

KW - castration-resistant prostate cancer (CRPC)

KW - ETS variant gene 6 (ETV6)

KW - SAM pointed domain containing ETS transcriptional factor (SPDEF)

KW - zinc finger and BTB domain-containing protein 46 (ZBTB46)

UR - http://www.scopus.com/inward/record.url?scp=85067818246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067818246&partnerID=8YFLogxK

U2 - 10.3390/ijms20112802

DO - 10.3390/ijms20112802

M3 - Review article

C2 - 31181727

AN - SCOPUS:85067818246

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

ER -